22nd Century Group: Disrupting The Plant-Based Markets With Improved Genetics

22nd Century Group, Inc. (NYSE: XXII) is a plant biotechnology company covering the tobacco, hemp and markets.

“At our core, think of us as the Intel Inside of cannabis. We’re a disruptive plant-based biotechnology company,” said CEO Jim Mish, presenting at the virtual Benzinga Cannabis Capital Conference on Thursday.

22nd Century was founded on a mission to bring forward a product able to reduce the harm caused by nicotine-based cigarettes, and later expanded to other plant lines including marijuana, hemp, and a third –still undisclosed– alkaloid-based plant.

The Tobacco Franchise: 22nd Century has developed a low nicotine strain of tobacco, which is aimed as a harm reduction alternative to the cigarette market.

“We have a very deep moat around our IP, certainly within the tobacco franchise. We own the IP on the low nicotine variant and we’ve got additional strains that we’re growing as we speak.”

The company’s VLN low nicotine brand has received FDA …

Full story available on Benzinga.com

More 22nd Century Group: Disrupting The Plant-Based Markets With Improved Genetics